Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment

Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment

The identification of specific epidermal growth factor receptor (EGFR)-activating mutations heralded a breakthrough in non-small-cell lung cancer (NSCLC) treatments, with the subsequent development of EGFR-tyrosine kinase inhibitor (TKIs) becoming the first-line therapy for patients harboring EGFR m...

Full description

Bibliographic Details
Main Authors:	Junnan Li, Hang Fai Kwok
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Cancers
Subjects:	lung cancer drug resistance mechanism EGFR mutation combination targeted therapy
Online Access:	https://www.mdpi.com/2072-6694/12/6/1587

Similar Items

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
by: Denis MG, et al.
Published: (2020-12-01)

Clinical Features of EGFR Double Mutation in Non-small Cell Lung Cancer
by: Mengyao WANG, et al.
Published: (2018-08-01)

Characteristics of Epidermal Growth Factor Receptor with Rare Mutations in Non-small Cell Lung Cancer and the Effect of EGFR Tyrosine Kinase Inhibitors on Them
by: Yunshu SHI, et al.
Published: (2019-05-01)

Dynamic Evaluation of Circulating miRNA Profile in <i>EGFR</i>-Mutated NSCLC Patients Treated with EGFR-TKIs
by: Alessandro Leonetti, et al.
Published: (2021-06-01)

Case Report: EGFR-Positive Early-Stage Lung Adenocarcinoma Transforming to Squamous Cell Carcinoma After TKI Treatment
by: Jiatao Liao, et al.
Published: (2021-06-01)

Activity of tarloxotinib‐E in cells with EGFR exon‐20 insertion mutations and mechanisms of acquired resistance
by: Masaya Nishino, et al.
Published: (2021-05-01)

Targeting AXL in NSCLC
by: Zaman A, et al.
Published: (2021-08-01)

Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor  Receptor Mutations in Non-small Cell Lung Cancer
by: Xue YANG, et al.
Published: (2015-08-01)

Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways
by: S Michael Rothenberg, et al.
Published: (2015-02-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
by: Kenneth K. W. To, et al.
Published: (2021-05-01)

Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
by: Helano C. Freitas, et al.
Published: (2020-07-01)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
by: Xiaojing Du, et al.
Published: (2021-05-01)

Clinical Observation of Translating to Small Cell Lung Cancer Following Treatment with EGFR-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma
by: Shuping XUE, et al.
Published: (2015-10-01)

Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
by: S.E.D.C. Jorge, et al.
Published: (2014-11-01)

Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective
by: Jing Zhu, et al.
Published: (2021-09-01)

EGFR testing and clinical management of advanced NSCLC: a Galician Lung Cancer Group study (GGCP 048-10)
by: Vázquez S, et al.
Published: (2016-02-01)

Clinical Analysis of 107 NSCLC Patients Harboring KRAS Mutation
by: Quan ZHANG, et al.
Published: (2016-05-01)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
by: Wu Z, et al.
Published: (2019-10-01)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang Fen, et al.
Published: (2012-08-01)

Discordance of Mutation Statuses of Epidermal Growth Factor Receptor and K-ras between Primary Adenocarcinoma of Lung and Brain Metastasis
by: Kun-Ming Rau, et al.
Published: (2016-04-01)

Targeting KRAS in Cancer: Promising Therapeutic Strategies
by: Lisa Maria Mustachio, et al.
Published: (2021-03-01)

Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
by: Zachary Schrank, et al.
Published: (2018-07-01)

Ionizing Radiation Reduces TKI Resistance Caused by T790M Mutation in NSCLC Cell Lines
by: Jing LI, et al.
Published: (2015-08-01)

Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
by: Jingpei Li, et al.
Published: (2020-07-01)

Clinical Characteristics and Outcomes of Lung Cancer Patients  with EGFR Mutations in Exons 19 and 21
by: Renwang LIU, et al.
Published: (2014-11-01)

EGFR mutated lung cancer: current therapies and potential future treatments
by: Polio, Andrew
Published: (2016)

Erratum: Neoadjuvant Four-Drug Combination Therapy for NSCLC With EGFR Mutation Avoiding Total Pneumonectomy
by: Frontiers Production Office
Published: (2020-07-01)

Response to the Combination of Osimertinib, Dabrafenib, and Trametinib in Leptomeningitis From EGFR-Mutant NSCLC With Acquired BRAF V600E Mutation: A Case Report
by: Orion Valet, et al.
Published: (2021-06-01)

A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
by: Li Liu, et al.
Published: (2021-10-01)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
by: Yuchen Bai, et al.
Published: (2018-12-01)

Translational Research on Epidermal Growth Factor Receptor Gene Mutations in Targeted Therapy for Patients with Advanced Non-Small Cell Lung Cancer
by: Xiao-yan WANG, et al.
Published: (2015-12-01)

EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry
by: Zohra Mraihi, et al.
Published: (2018-08-01)

Combination of Crizotinib and Osimertinib in T790M+ EGFR-Mutant Non-Small Cell Lung Cancer with Emerging MET Amplification Post-Osimertinib Progression in a 10-Year Survivor: A Case Report
by: Miriam Blasi, et al.
Published: (2021-03-01)

AFATINIB IN THE TREATMENT OF METASTATIC AND LOCALLY ADVANCED LUNG ADENOCARCINOMA WITH EGFR MUTATIONS: NEW SIDES STUDIED POSSIBILITIES
by: E. V. Karabina, et al.
Published: (2017-11-01)

Role of EGFR Mutation Status in Patients with Stage III Non-squamous Non-small Cell Lung Cancer Treated with Chemoradiotherapy
by: Fuhai LI, et al.
Published: (2011-09-01)

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study
by: E. A. van de Stadt, et al.
Published: (2020-08-01)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
by: In Ae Kim, et al.
Published: (2018-07-01)

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
by: Wolfgang Schuette, et al.
Published: (2018-02-01)

Targeted Therapies in Early Stage NSCLC: Hype or Hope?
by: Alex Friedlaender, et al.
Published: (2020-08-01)